Rhabdomyosarcoma is the most common soft-tissue sarcoma in children and affects muscles in any part of the body. Among patients diagnosed with non-metastasized disease, about 80 percent survive at least five years, although they may experience substantial treatment-related toxic effects. However, for those with metastatic disease, the five-year survival rate is about 30 percent even with aggressive treatment…
Young cancer patients were also more likely than children who experience other stressful events to report having benefited from the experience. Reported benefits included developing greater empathy and growing closer to family and friends. The study included 255 St…
The research, published in Nature, raises several intriguing possibilities for further investigation that might lead to improved treatments for blood cancers and increased safety and effectiveness of chemotherapy. Before the finding, blood-forming stem cells were thought to be regulated similarly in both males and females, according to the paper’s senior author, Dr. Sean Morrison, Director of CRI, Professor of Pediatrics, and the Mary McDermott Cook Chair in Pediatric Genetics at UT Southwestern Medical Center…
"People don’t always understand genetic information, so there’s confusion," says study author Mary B. Daly, MD, PhD, chair of the Department of Clinical Genetics at Fox Chase. …
"The prevalence of these symptoms accounts for a huge variance in physical, mental and social domains of quality of life among survivors," said I-Chan Huang, Ph.D., an associate professor of health outcomes and policy in the UF College of Medicine and the lead author of the study. "If we think symptoms are the key to patients’ quality of life, then if we can better manage their symptoms, we can improve their daily functional status and quality of life." Huang, also a member of UF’s Institute for Child Health Policy, teamed with researchers from St. Jude Children’s Research Hospital in Memphis to conduct the study, which was published in the Nov. 20 issue of the Journal of Clinical Oncology…
"We undertook this study because we wanted to learn what was driving the growth of these tumors and how best to treat them," says the study’s co-principal investigator, Dr. …
Two of the first three chronic lymphocytic leukemia (CLL) patients who participated in the study, which started in the summer of 2010, remain in remission, with tests revealing reprogrammed cells still circulating in their bodies, on guard to combat tumor cells that may reappear in the future. Additional highlights of the new research results include an 89 percent complete response rate among adult and pediatric patients with acute lymphoblastic leukemia (ALL). "In a very short time, we’ve learned so much about how CTL019 works and how powerful it can be," said the research team’s leader, Carl H…
Eight of the nine boys registered to date in the new trial are alive and well, with functioning immune systems and free of infections associated with SCID-X1, between nine and 36 months following treatment, according to Sung-Yun Pai, MD, a pediatric hematologist-oncologist from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. She presented the findings at the 55th annual meeting of the American Society of Hematology on behalf of the Transatlantic Gene Therapy Consortium (TAGTC). The investigators continue to monitor the children for signs of treatment-associated leukemia, which developed three to five years post-treatment in the prior trial. …
HPV vaccine coverage among teenagers has increased since the vaccine was licensed in 2006 but it still remains low compared with other recommended vaccinations. Most HPV infections will clear on their own, but persistent infections can progress to precancers or cancers, including cervical, vulvar, vaginal, penile and anal cancer, as well as cancers of the mouth and throat. Vaccination is recommended for both girls and boys, based on age requirements for the specific vaccines, according to the study background. Dawn M. …
The study was conducted on mice. But if shown to work similarly in humans, the inexpensive, widely available household chemical could provide a new way to treat skin damage caused by radiation therapy, excess sun exposure or aging. Dilute bleach baths have been used for decades to treat moderate to severe eczema in humans, but it has not been clear until now why they work…